First-in-human multicenter phase i study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 1, 2016, Pages 155-162

  Owonikoko, Taofeek Kunle ^a   Hussain, Arif ^b   Stadler, Walter Michael ^c   Smith, David C ^d   Kluger, Harriet ^e   Molina, Ana M ^f   Gulati, Parul ^g   Shah, Aadhar ^g   Ahlers, Christoph Matthias ^g   Cardarelli, Pina M ^g   Cohen, Lewis J ^g  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e YALE UNIVERSITY   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antibody drug conjugate; BMS 936561; CD70; Pharmacokinetic; Phase

Indexed keywords

BMS 936561; CD70 ANTIGEN; DRUG; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ALKYLATING AGENT; ANTIBODY CONJUGATE; INDOLE DERIVATIVE; MDX-1203;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FACE EDEMA; FATIGUE; FEMALE; HUMAN; HYPERPIGMENTATION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY FAILURE; THROMBOCYTOPENIA; VOMITING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; KIDNEY NEOPLASMS; LYMPHOMA, B-CELL; MIDDLE AGED; PATHOLOGY;

AGED; ANTIGENS, CD70; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCONJUGATES; INDOLES; KIDNEY NEOPLASMS; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 84954072873     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2909-2     Document Type: Article

References (26)

1. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, Grewal IS, Law CL (2008) Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 14(23):7763-7772. doi: 10.1158/1078-0432.CCR-08-0493
2. Teicher BA, Chari RV (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17(20):6389-6397. doi: 10.1158/1078-0432.CCR-11-1417
3. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL (2007) Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109(3):1185-1192. doi: 10.1182/blood-2006-07-034017
4. Thevanayagam L, Bell A, Chakraborty I, Sufi B, Gangwar S, Zang A, Rangan V, Rao C, Wang Z, Pan C, Chong C, Cardarelli P, Deshpande S, Srinivasan M (2013) Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications. Bioanalysis 5(9):1073-1081. doi: 10.4155/bio.13.57
5. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S (1994) The cloning of CD70 and its identification as the ligand for CD27. J Immunol 152(4):1756-1761
6. Borst J, Hendriks J, Xiao Y (2005) CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17(3):275-281. doi: 10.1016/j.coi.2005.04.004
7. Nilsson A, de Milito A, Mowafi F, Winberg G, Bjork O, Wolpert EZ, Chiodi F (2005) Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol 33(12):1500-1507. doi: 10.1016/j.exphem.2005.10.005
8. Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, Lu LS, Leach BI, Mason S, Stamps AC, Boyd RS, Pezzella F, Gatter KC, Harris AL (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 95(3):298-306. doi: 10.1038/sj.bjc.6603222
9. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J (2005) CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 173(6):2150-2153. doi: 10.1097/01.ju.0000158121.49085.ba
10. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66(4):2328-2337. doi: 10.1158/0008-5472.CAN-05-2883
11. Grewal IS (2008) CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets 12(3):341-351. doi: 10.1517/14728222.12.3.341
12. McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, Lyon R, Alley SC, Gerber HP, Carter PJ (2008) Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 7(9):2913-2923. doi: 10.1158/1535-7163.MCT-08-0295
13. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14(19):6171-6180. doi: 10.1158/1078-0432.CCR-08-0916
14. Boger DL, Johnson DS, Yun W, Tarby CM (1994) Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity. Bioorgan Med Chem 2(2):115-135
15. Gomi K, Kobayashi E, Miyoshi K, Ashizawa T, Okamoto A, Ogawa T, Katsumata S, Mihara A, Okabe M, Hirata T (1992) Anticellular and antitumor activity of duocarmycins, novel antitumor antibiotics. Jpn J Cancer Res 83(1):113-120
16. Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J (2007) Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer 38(1):10-14
17. Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, Alberts SR, Kaur JS, Braich TA, Leitch JM, Creagan ET (2002) Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol 25(3):308-312
18. Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C (2000) A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. Invest New Drugs 18(2):193-197
19. Schwartz GH, Patnaik A, Hammond LA, Rizzo J, Berg K, Von Hoff DD, Rowinsky EK (2003) A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Ann Oncol 14(5):775-782
20. Wang H, Rangan VS, Sung MC, Passmore D, Kempe T, Wang X, Thevanayagam L, Pan C, Rao C, Srinivasan M, Zhang Q, Gangwar S, Deshpande S, Cardarelli P, Marathe P, Yang Z (2015) Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Biopharm Drug Dispos. doi: 10.1002/bdd.1953
21. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783-1791. doi: 10.1056/NEJMoa1209124
22. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30(18):2183-2189. doi: 10.1200/JCO.2011.38.0410
23. Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A (2015) Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 125(8):1236-1243. doi: 10.1182/blood-2014-08-595801
24. Mack F, Ritchie M, Sapra P (2014) The next generation of antibody drug conjugates. Semin Oncol 41(5):637-652. doi: 10.1053/j.seminoncol.2014.08.001
25. Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri Kordestani L, Cortazar P, Ibrahim A, Justice R, Wang Y, Tang S, Booth B, Mehrotra N, Rahman A (2014) Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther 95(5):558-564. doi: 10.1038/clpt.2014.24
26. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P (2013) Bioanalysis of antibody-drug conjugates: American association of pharmaceutical scientists antibody-drug conjugate working group position paper. Bioanalysis 5(9):997-1006. doi: 10.4155/bio.13.38